🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#GileadNews: With Kite, a Gilead Company, we’re announcing the presentation of transformative cancer research at #ASCO25 and #EHA2025. Read more: gilead.inc/3GQyiEa

We’re proud to share that “The Adventure Jar,” a children’s book supporting families impacted by #MBC, has received two 2025 Bronze Anvil Awards from PRSA. Get a free copy: gilead.inc/4iZNRqd #AnvilAwards

We’re more than halfway to our goal to deliver 10+ transformative medicines in cancer, HIV, COVID-19 and liver disease by 2030. We’ll continue to help drive progress through pioneering internal discovery and development efforts.

When Emma was diagnosed with #TNBC, she didn't let it define her. There are so many ways cancer steals possibility, but at Gilead, we’re helping take it back. We’ll continue working to transform how cancer is treated — and we look forward to sharing our research at #ASCO25.

#GileadNews: We’re announcing topline results from our Phase 3 ASCENT-03 study in metastatic triple-negative breast cancer. This is a major milestone in the treatment of this aggressive and difficult-to-treat cancer, where progress has long been limited. gilead.inc/4kq3Xuy

At Gilead, we’re advancing new ways to help end the #HIV epidemic. In this episode of The Centrifuge Sessions, Magdeleine Hung, Director of Protein Therapeutics, shares insights on our pioneering work in HIV.

From new discoveries to reclaiming hope, we're driven by a collective goal - helping to bring more lite to people living with cancer. Ahead of #ASCO25, watch Gilead and Kite, a Gilead Company leaders share what that means to them.

With the launch of #CARTVision, we’re deepening our commitment to advancing cell therapy alongside Kite, a Gilead Company by joining an international coalition to expand access to these innovative treatments.

We’ve built our oncology pipeline to address challenging-to-treat conditions and bring more hope to people with cancer. We’re excited to be at #ASCO25 with Kite, a Gilead Company to showcase our bold approach to innovation and our work to reach patients earlier in their treatment journey.

#GileadNews: We're presenting late-breaking Phase 3 data in first-line metastatic triple-negative breast cancer at #ASCO25. These results underscore our commitment to transforming how cancer is treated. Learn more: gilead.inc/4kp5dhS

We’re encouraged by early results of a Penn Medicine Phase 1 clinical study of CAR T-cell therapy in recurrent GBM in Nature Medicine. As the potential of CAR T expands beyond blood cancers, so does the hope for new options for patients. #ASCO25

We know that inclusion can drive innovation. As we mark the start of #PrideMonth, Gary Ryan, a leader in our Pride Alliance employee resource group, shares how creating space for authenticity can strengthen teams and spark bold ideas. #GileadLife

At Gilead and Kite, a Gilead Company, we’re applying our combined expertise and learnings to advance next-generation cancer treatments. See how we’re working together to move cell therapy beyond blood cancer to address solid tumors. gilead.inc/4dIy91P #ASCO25

What would you tell your former self living with cancer? At #ASCO25, two advocates left powerful voicemails to their past selves – messages of reflection, resilience and the extraordinary fight to take back possibility in the face of cancer. Hear their inspiring stories.

Yesterday kicked off our annual Month of Service in Foster City. With Samaritan House, nearly 100 Gilead volunteers assembled 1,000 backpacks filled with supplies for K–2nd grade students in the San Mateo School District. Watch the KRON4 News coverage: gilead.inc/43IOU8B

On #HLTSAD, we honor the strength and stories of those who have lived with #HIV for decades - including Kim Canady. Our work is rooted in partnership with the communities most affected by the epidemic to help ensure everyone lives healthier lives. gilead.inc/3ZReozc

Congratulations to Gilead's Moupali Das for being awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award. This recognizes the pivotal role she played as part of the team in designing the most diverse HIV prevention studies ever conducted.

100+ Gilead employees. 2,800 total riders. 545 miles. 1 final ride. As a longtime partner, our team rode, volunteered and cheered at AIDS/LifeCycle — supporting an incredible community and the impactful work of the San Francisco AIDS Foundation and the Los Angeles LGBT Center.

More than 100 volunteers packed 1,000 backpacks for local students with Samaritan House during our first Month of Service event. We’re committed to making a difference in the world through our work and our employees, who make a positive impact in the communities we serve.

We’re excited to share that our partner @Arcellx presented new data from the pivotal Phase 2 iMMagine-1 study in relapsed/refractory multiple myeloma at #EHA2025 today.